ライフサイエンスコーパス: mebendazole

1 osition was known (Esomeprazole) or unknown (Mebendazole).

2 arly deworming (n = 970) with 500 mg generic mebendazole.

3 the World Health Organization essential drug Mebendazole.

4 preventive chemotherapy with albendazole and mebendazole.

5 ese children (14%) filled a prescription for mebendazole, 102,482 of the children (11%) had a househo

6 r with oxantel pamoate-albendazole than with mebendazole (31.2% vs. 11.8%, P=0.001), as was the egg-r

7 tine, 26 ng/L), and two anthelmintic agents (mebendazole, 65 ng/L, and albendazole, 48 ng/L) could be

8 individual prescriptions filled for the drug mebendazole against Enterobius vermicularis for all chil

9 folic acid for 90 d and single-dose (500 mg) mebendazole among severely anemic pregnant women in peri

10 nificantly increased the LMIs, we identified mebendazole, an anti-helminthic clinically used for deca

11 re, we used the TMFS method to discover that mebendazole, an antiparasitic with recently discovered a

12 experimental evaluations, we discovered that mebendazole, an approved anthelmintic drug, could select

13 luding post-exposure prophylaxis (PEP) using mebendazole and advised the public to seek medical advic

14 The benzimidazole anthelmintics, mebendazole and albendazole, are commonly used to remove

15 hiobarituric acid and the antihelmintic drug mebendazole and that some functionals substantially unde

16 approaches using single-dose albendazole or mebendazole are effective for ascariasis, less so for ot

17 Albendazole and mebendazole are ubiquitously used, but they are not suff

18 Two benzimidazoles, albendazole and mebendazole, are currently used in STN mass drug adminis

19 We identify dimaprit and mebendazole as a drug combination which induces myeloid

20 ; albendazole at a single dose of 400 mg; or mebendazole at a single dose of 500 mg.

21 quent CoMSIA and kNN analyses indicated that mebendazole bears the favorable molecular features that

22 ns are typically treated with albendazole or mebendazole, but both drugs show low efficacy against T.

23 experimentally reported crystal structure of mebendazole form B features the incorrect tautomer-a pre

24 in all groups and was higher in the enhanced mebendazole group compared with the standard group (P <

25 concern because of the variable efficacy of mebendazole, high rates of post-treatment reinfection an

26 We determined that treatment with mebendazole induces dramatic differentiation of leukemia

27 We confirmed experimentally that mebendazole inhibits VEGFR2 kinase activity and angiogen

28 1.65-15.59]; dERR, 0.51 [95% CI, .50-.52]), mebendazole-ivermectin (RR, 3.37 [95% CI, 2.20-5.16]), a

29 ole (49mugkg(-1)), sulfamethazine (<LOQ) and mebendazole (<LOQ) were found.

30 These findings suggest that mebendazole may be utilized as a low toxicity therapeuti

31 eatment of T. spiralis-infected rodents with mebendazole (MBZ) causes a reduction in the size of infe

32 Mebendazole (MBZ) is an efficacious anthelmintic with kn

33 Mebendazole (MBZ), has been used as antitubulin drug.

34 ified Cry5B, the benzimidazole anthelminthic mebendazole, or buffer.

35 were significantly lower than the rates with mebendazole (P=0.02 for the comparison of cure rates).

36 sehold peer who was registered with a filled mebendazole prescription, and the remaining 689,884 chil

37 Multivitamins and the enhanced mebendazole regimen had a modest benefit over and above

38 lure (with diethylcarbamazine and levamisole-mebendazole, respectively).

39 Levamisole plus mebendazole significantly reduced prevalence of hookworm

40 0s, whereas routine antenatal deworming with mebendazole started in the 1980s.

41 dministration (generally with albendazole or mebendazole) to at-risk populations and improvements in

42 ced worm burdens that were comparable to the mebendazole-treated animals.

43 inflammatory disease according to history of mebendazole treatment prescribed to children in the stud

44 Furthermore, mebendazole treatment significantly extended the surviva

45 parison of drugs (praziquantel, albendazole, mebendazole, tribendimidine, or combinations of these dr

46 ard treatment alone (control) or with 100 mg mebendazole twice daily for 3 d or 90 d of daily multivi

47 We tested the differentiation activity of mebendazole using primary leukemia blast cells isolated